Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications
Barış Afşar, Mads Hornum, Rengin Elsürer Afşar, et al.
Mitochondrion (2021) Vol. 58, pp. 72-82
Closed Access | Times Cited: 19

Showing 19 citing articles:

Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease
Miguel Fontecha‐Barriuso, Ana M. López-Diaz, Juan Guerrero‐Mauvecin, et al.
Antioxidants (2022) Vol. 11, Iss. 7, pp. 1356-1356
Open Access | Times Cited: 62
Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis
Mehmet Kanbay, Laura Țăpoi, Carina Ureche, et al.
International Urology and Nephrology (2021) Vol. 54, Iss. 4, pp. 827-841
Closed Access | Times Cited: 37
The Mitochondrion: A Promising Target for Kidney Disease
Cem Tanrıöver, Sidar Çöpür, Duygu Uçku, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 570-570
Open Access | Times Cited: 14
Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model
Ephraim B. Winzer, Antje Schauer, Erik Langner, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 10989-10989
Open Access | Times Cited: 22
Roles of NAD+ in Acute and Chronic Kidney Diseases
Marya Morevati, Evandro Fei Fang, Maria L. Mace, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 137-137
Open Access | Times Cited: 19
Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Barış Afşar, Rengin Elsürer Afşar
Clinical Nutrition (2023) Vol. 42, Iss. 12, pp. 2338-2352
Closed Access | Times Cited: 13
MC16 promotes mitochondrial biogenesis and ameliorates acute and diabetic nephropathy
Austin Thompson, Kevin Hurtado, Jaroslav Janda, et al.
British Journal of Pharmacology (2025)
Closed Access
SGLT2 inhibitor dapagliflozin mitigates skeletal muscle pathology by modulating key proteins involved in glucose and ion homeostasis in an animal model of heart failure
Elena Conte, Paola Imbrici, Giorgia Dinoi, et al.
European Journal of Pharmacology (2025), pp. 177617-177617
Open Access
Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series
Junji Nishida, Mayuko Yamakawa, Shoko Miura, et al.
CEN Case Reports (2025)
Open Access
Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
Barış Afşar, Rengin Elsürer Afşar, Atalay Demiray, et al.
Clinical Kidney Journal (2022) Vol. 15, Iss. 7, pp. 1275-1283
Open Access | Times Cited: 17
Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
Sara Volpe, Alfredo Vozza, Giuseppe Lisco, et al.
Nutrients (2024) Vol. 16, Iss. 22, pp. 3841-3841
Open Access | Times Cited: 3
Renal ciliopathies: promising drug targets and prospects for clinical trials
Laura A. Devlin, Praveen Dhondurao Sudhindar, John A. Sayer
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 4-5, pp. 325-346
Open Access | Times Cited: 8
Sodium‐glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence
Mehmet Kanbay, Atalay Demiray, Barış Afşar, et al.
Nephrology (2021) Vol. 26, Iss. 12, pp. 1007-1017
Open Access | Times Cited: 18
Sodium–glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms
Barış Afşar, Rengin Elsürer Afşar
Pharmacological Reports (2022) Vol. 75, Iss. 1, pp. 44-68
Closed Access | Times Cited: 13
Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches
Phoom Narongkiatikhun, Nipon Chattipakorn, Nipon Chattipakorn
Journal of Cellular and Molecular Medicine (2021) Vol. 26, Iss. 2, pp. 249-273
Open Access | Times Cited: 15
The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets
Masanobu Takasu, Seiji Kishi, Hajime Nagasu, et al.
Kidney International Reports (2024)
Open Access | Times Cited: 1
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Domenico Tricò, Anna Solini
Advances in Chronic Kidney Disease (2021) Vol. 28, Iss. 4, pp. 328-336
Closed Access | Times Cited: 8
Renal Protective Mechanisms of Shenyuan Particle in Db/Db Mice: A Study Based on Network Pharmacology
Guoshuang Zhu, Lan Wang, Zenan Wu, et al.
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-11
Open Access | Times Cited: 3
Control of Mitochondrial Quality: A Promising Target for Diabetic Kidney Disease Treatment
Q Li, Jin Shang, Reiko Inagi
Kidney International Reports (2024)
Open Access
Page 1

Scroll to top